Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma
Business Wire•24/07/2026•08:00 ET
0
Whiz Insights
Get started
Create a free account to read the full story.